Cybin Announces Sponsorship of a Kernel Flow Feasibility Study to Measure Ketamine’s Psychedelic Effects on Cerebral… Jun 1, 2021
Cybin Granted IRB Approval for Phase II Clinical Trials of its Sublingual Psilocybin Formulation for the Treatment of… May 18, 2021
PharmaTher Announces FDA Approval of Ketamine IND In The Treatment of Parkinson’s Disease May 17, 2021
PsyBio Therapeutics Increases Intellectual Property Portfolio with Filing of Novel Genetic Optimization Pathways for… May 12, 2021
